Kiniksa Pharmaceuticals International, plc
corporate_fare Company Profile
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for KNSA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-30, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for KNSA spans 144, 10-Q, 8-K, 4.
Recent high-impact activity:
- Kiniksa CEO/Chairman Patel Notices $51.6M Sale, Largest of Four Officer 144s
- Kiniksa 10-Q: Q3 Revenue Up 58% to $286.0M, Net Income $47.3M, $568.8M Cash
- Arcalyst Guidance Raised to $1.05B as Q3 Revenue Beats by $25M; Shares Jump 20%
- Kiniksa Posts Q3 EPS of 56 Cents
- Kiniksa Q2 ARCALYST Revenue Surges 55% to $243.6M; Full-Year Guidance Raised to $980–$995M
Financial Snapshot
Short Interest & Short Volume
3.89 days to coverFINRA reported short interest of 4,294,644 shares in KNSA as of the October 30, 2026 settlement, a 14.1% increase from the prior period — about 3.9 days to cover at its recent average daily volume. On November 20, 2026, 58.7% of KNSA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.